Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.28 -1.97 (-4.00%)
Streaming Delayed Price Updated: 12:17 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
News headline image
What's Going On With Nektar Therapeutics Stock On Thursday? ↗
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results. 
Via Benzinga
News headline image
Why Is Sanofi Stock Falling Thursday? ↗
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. 
Via Benzinga
News headline image
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors ↗
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise. 
Via Benzinga
News headline image
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar' ↗
Can anything beat out Dupixent's "compelling bar" for effectiveness? 
Via Investor's Business Daily
Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More ↗
Via Stocktwits
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification ↗
Via Stocktwits
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
News headline image
This Monster Beverage Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
News headline image
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales ↗
Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi. 
Via Benzinga
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca ↗
Via Stocktwits
News headline image
What's Driving the Market Sentiment Around Sanofi? ↗
 
Via Benzinga
News headline image
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
News headline image
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients ↗
FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes. 
Via Benzinga
News headline image
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines ↗
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals. 
Via Benzinga
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount ↗
Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount. 
Via Benzinga
Topics Earnings
News headline image
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales ↗
Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward. 
Via Benzinga
News headline image
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save. 
Via The Motley Fool
Topics Artificial Intelligence Retirement
News headline image
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel ↗
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline. 
Via Benzinga
News headline image
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates ↗
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies. 
Via Benzinga
News headline image
Why Thermo Fischer Stock Is Rising Wednesday ↗
Thermo Fisher beat Q2 estimates, raised its 2025 guidance, and announced a CFO transition as easing tariffs support an improved outlook. 
Via Benzinga
Topics World Trade
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Humana Moves To Cut Prior Authorization Delays, Streamline Care Approvals ↗
Humana will cut prior authorizations, launch a gold card program, and speed up electronic approvals to improve care access and transparency by 2026. 
Via Benzinga
News headline image
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
News headline image
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy ↗
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.